Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2022

View Archived Issues

CFB inhibitors identified by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine

ScinnoHub Pharmaceutical discovers plasmin inhibitors

Discovery of novel candidates for the treatment of Chagas disease

Impact Biomedical announces development of Quantum antihistamine

SBIR grant supports STRM.BIO's development of EV technology as gene therapy delivery platform

ExcellGene plays role in CEPI-funded consortium to advance new vaccine concept for SARS-CoV-2

Medshine Discovery describes new complement factor B inhibitors

C-65780 stabilizes voltage-gated sodium channels and produces pain relief in vivo

Suzhou Zelgen Biosciences identifies new aryl hydrocarbon receptor antagonists

New MAT2A inhibitors discovered at Jiangsu Simcere Pharmaceutical R&D

Monoclonal antibody pairs "zipper" to target cancer

Amubarvimab/romlusevimab retains neutralizing activity against live Omicron subvariants

Vitamin B6 benzohydrazide platinum(II) complexes overcome cisplatin resistance in tumors

ZyVersa receives grant to assess potential of IC-100 to block neuroinflammation in Parkinson's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.